Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Precision BioSciences (NASDAQ:DTIL) Critical Comparison

Precision BioSciences (NASDAQ:DTIL – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Precision BioSciences and Aurinia Pharmaceuticals”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Precision BioSciences $34.26 million 5.75 -$45.72 million ($1.24) -5.69
Aurinia Pharmaceuticals $283.05 million 7.29 $287.20 million $2.29 6.72

Aurinia Pharmaceuticals has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Precision BioSciences has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Institutional and Insider Ownership

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Precision BioSciences and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Precision BioSciences -96.73% -56.69% -27.63%
Aurinia Pharmaceuticals 97.68% 22.99% 17.99%

Analyst Recommendations

This is a summary of recent recommendations for Precision BioSciences and Aurinia Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision BioSciences 1 0 4 0 2.60
Aurinia Pharmaceuticals 0 3 2 1 2.67

Precision BioSciences currently has a consensus price target of $32.25, indicating a potential upside of 357.45%. Aurinia Pharmaceuticals has a consensus price target of $17.33, indicating a potential upside of 12.55%. Given Precision BioSciences’ higher possible upside, equities analysts clearly believe Precision BioSciences is more favorable than Aurinia Pharmaceuticals.

Summary

Aurinia Pharmaceuticals beats Precision BioSciences on 11 of the 14 factors compared between the two stocks.

About Precision BioSciences

(Get Free Report)

Precision BioSciences is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases. The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.